Aethlon Medical is closely monitoring the Bird Flu situation and stands ready to work alongside hospitals, health agencies and the FDA if existing therapies prove inadequate.
v3.25.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| OPERATING EXPENSES | ||||
| Professional fees | $ 377,877 | $ 668,586 | $ 1,563,995 | $ 2,778,335 |
| Payroll and related expenses | 620,487 | 1,919,305 | 3,248,187 | 4,233,970 |
| General and administrative | 816,383 | 979,197 | 2,525,220 | 3,138,289 |
| Total operating expenses | 1,814,747 | 3,567,088 | 7,337,402 | 10,150,594 |
| OPERATING LOSS | (1,814,747) | (3,567,088) | (7,337,402) | (10,150,594) |
| OTHER INCOME | ||||
| Interest Income | (59,964) | (100,967) | (204,206) | (367,838) |
| NET LOSS | (1,754,783) | (3,466,121) | (7,133,196) | (9,782,756) |
| OTHER COMPREHENSIVE INCOME (LOSS) | (13,057) | 7,951 | (10,085) | 4,522 |
| COMPREHENSIVE LOSS | $ (1,767,840) | $ (3,458,170) | $ (7,143,281) | $ (9,778,234) |
| Basic loss per share attributable to common stockholders | $ (0.13) | $ (1.37) | $ (0.61) | $ (3.95) |
| Diluted loss per share attributable to common stockholders | $ (0.13) | $ (1.37) | $ (0.61) | $ (3.95) |
| Weighted average number of common shares outstanding - basic | 13,962,266 | 2,516,511 | 11,801,655 | 2,477,282 |
| Weighted average number of common shares outstanding - diluted | 13,962,266 | 2,516,511 | 11,801,655 | 2,477,282 |
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of tax expense (benefit) allocated to other comprehensive income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|